Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modif...

Полное описание

Библиографические подробности
Главные авторы: Eustace, A, Irlam, J, Taylor, J, Denley, H, Agrawal, S, Choudhury, A, Ryder, D, Ord, J, Harris, A, Rojas, A, Hoskin, P, West, C
Формат: Journal article
Язык:English
Опубликовано: 2013